|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Cash and due from banks | ||||||||||||||||
| Interest-bearing deposits in banks | ||||||||||||||||
| Federal funds sold | ||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||
| Securities available for sale, at fair value ($209,077 at amortized cost, $0 allowance for credit losses at March 31, 2025; $207,595 at amortized cost, $0 allowance for credit losses at December 31, 2024) | ||||||||||||||||
| Securities held to maturity, at amortized cost ($16,405 at fair value, $0 allowance for credit losses at March 31, 2025; $16,032 at fair value, $0 allowance for credit losses at December 31, 2024) | ||||||||||||||||
| Other equity securities, at fair value | ||||||||||||||||
| Restricted equity securities, at cost | ||||||||||||||||
| Loans held for sale | ||||||||||||||||
| Loans, net of unearned income | ||||||||||||||||
| Less allowance for credit losses | ||||||||||||||||
| Loans, net | ||||||||||||||||
| Premises and equipment, net | ||||||||||||||||
| Accrued interest receivable | ||||||||||||||||
| Bank owned life insurance | ||||||||||||||||
| Annuities | ||||||||||||||||
| Foreclosed assets | ||||||||||||||||
| Goodwill | ||||||||||||||||
| Core deposit intangible | ||||||||||||||||
| Other assets | ||||||||||||||||
| Total assets | ||||||||||||||||
| Liabilities and Stockholders' Equity | ||||||||||||||||
| Liabilities: | ||||||||||||||||
| Deposits: | ||||||||||||||||
| Noninterest-bearing | ||||||||||||||||
| Interest-bearing | ||||||||||||||||
| Total deposits | ||||||||||||||||
| Other borrowings | ||||||||||||||||
| FHLB advances | ||||||||||||||||
| Subordinated notes | ||||||||||||||||
| Accrued interest payable | ||||||||||||||||
| Other liabilities | ||||||||||||||||
| Total liabilities | ||||||||||||||||
| Stockholders' equity: | ||||||||||||||||
| Preferred stock, $0.01 par value, 2,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2025 and December 31, 2024 | ||||||||||||||||
| Common stock, $5 par value, 30,000,000 shares authorized; 9,922,180 and 9,889,260 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | ||||||||||||||||
| Capital surplus | ||||||||||||||||
| Retained earnings | ||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||
| Unvested restricted stock | ||||||||||||||||
| Vested restricted stock units | ||||||||||||||||
| Total stockholders' equity | ||||||||||||||||
| Total liabilities and stockholders' equity |
Loading...
